You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
McKesson
AstraZeneca
Dow
Colorcon

Last Updated: May 16, 2021

DrugPatentWatch Database Preview

KERYDIN Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Kerydin patents expire, and when can generic versions of Kerydin launch?

Kerydin is a drug marketed by Anacor Pharms Inc and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-five patent family members in twenty-three countries.

The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the tavaborole profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Kerydin

A generic version of KERYDIN was approved as tavaborole by ENCUBE on October 13th, 2020.

  Get Started for $10

Drug patent expirations by year for KERYDIN
Drug Prices for KERYDIN

See drug prices for KERYDIN

Recent Clinical Trials for KERYDIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
PfizerPhase 4

See all KERYDIN clinical trials

Pharmacology for KERYDIN
Paragraph IV (Patent) Challenges for KERYDIN
Tradename Dosage Ingredient NDA Submissiondate
KERYDIN SOLUTION;TOPICAL tavaborole 204427 2018-07-09

US Patents and Regulatory Information for KERYDIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Anacor Pharms Inc KERYDIN tavaborole SOLUTION;TOPICAL 204427-001 Jul 7, 2014 AB RX Yes Yes   Get Started for $10   Get Started for $10 Y   Get Started for $10
Anacor Pharms Inc KERYDIN tavaborole SOLUTION;TOPICAL 204427-001 Jul 7, 2014 AB RX Yes Yes   Get Started for $10   Get Started for $10 Y   Get Started for $10
Anacor Pharms Inc KERYDIN tavaborole SOLUTION;TOPICAL 204427-001 Jul 7, 2014 AB RX Yes Yes   Get Started for $10   Get Started for $10 Y   Get Started for $10
Anacor Pharms Inc KERYDIN tavaborole SOLUTION;TOPICAL 204427-001 Jul 7, 2014 AB RX Yes Yes   Get Started for $10   Get Started for $10 Y   Get Started for $10
Anacor Pharms Inc KERYDIN tavaborole SOLUTION;TOPICAL 204427-001 Jul 7, 2014 AB RX Yes Yes   Get Started for $10   Get Started for $10 Y   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for KERYDIN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2343304 2020C/531 Belgium   Get Started for $10 PRODUCT NAME: CRISABOROLE, OPTIONEEL IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: EU/1/19/1421 20200401
2343304 122020000038 Germany   Get Started for $10 PRODUCT NAME: CRISABOROL, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES DAVON; REGISTRATION NO/DATE: EU/1/19/1421 20200327
2343304 PA2020524 Lithuania   Get Started for $10 PRODUCT NAME: KRISABOROLAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS FORMOJE; REGISTRATION NO/DATE: EU/1/19/1421 20200327
2343304 2090017-1 Sweden   Get Started for $10 PRODUCT NAME: CRISABOROLE, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT; REG. NO/DATE: EU/1/19/1421 20200401
2343304 301049 Netherlands   Get Started for $10 PRODUCT NAME: CRISABOROLE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/19/1421 20200401
2343304 LUC00157 Luxembourg   Get Started for $10 PRODUCT NAME: CRISABOROLE, EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE (CONFORME AUX REVENDICATIONS 30 ET 33 DU BREVET DE BASE); AUTHORISATION NUMBER AND DATE: EU/1/19/1421 20200401
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
Baxter
Express Scripts
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.